Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 901–1,000 of 1,056
Hwang, K.-T., Kim, J., Jung, J., Chang, J. H., Chai, Y. J., Oh, S. W., Oh, S., Kim, Y. A., Park, S. B., & Hwang, K. R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2782 · Cited by 179
“Previous studies have reported favorable prognosis of HRc(þ) breast cancers (11, 12, 14) and adverse prognosis of HER2(þ) breast cancers (11, 12, 14, 30, 31).”
ResultPeptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein
Disis, M. L., Gralow, J. R., Bernhard, H., Hand, S. L., Rubin, W. D., & Cheever, M. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3151 · Cited by 179
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth
Mann, M., Sheng, H., Shao, J., Williams, C. S., Dubois, R. N., Pisacane, P. I., & Sliwkowski, M. X. (2001) · Gastroenterology · doi:10.1053/gast.2001.24844 · Cited by 179
Ulaner, G. A., Lyashchenko, S. K., Riedl, C., Ruan, S., Zanzonico, P. B., Lake, D., Jhaveri, K., Zeglis, B., Lewis, J. S., & O’Donoghue, J. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202010 · Cited by 179
Nanomedicine-based tumor photothermal therapy synergized immunotherapy
Shang, T., Yu, X., Han, S., & Yang, B. (2020) · Biomaterials Science · doi:10.1039/d0bm01158d · Cited by 179
Overexpression of HER2/neu in solid tumours: an immunohistochemical survey
Koeppen, H., Wright, B. D., Burt, A. D., Quirke, P., McNicol, A. M., Dybdal, N. O., Sliwkowski, M. X., & Hillan, K. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01084.x · Cited by 179
Spiridon, C., Ghetie, M.-A., Uhr, J. W., Marcheş, R., Li, J. L., Shen, G. L., & Vitetta, E. S. (2002) · PubMed · Cited by 179
Schettini, F., Pascual, T., Conte, B., Chic, N., Brasó-Maristany, F., Galván, P., Martínez, O., Adamo, B., Vidal, M., Muñoz, M., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101965 · Cited by 178
Bai, W., Ye, X., Zhang, M., Zhu, H., Xi, W., Huang, X., Zhao, J., Gu, B., Zheng, G., Yang, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28782 · Cited by 178
“Overexpression of ErbB2/HER2 occurs in 20– 25% of human breast cancers, and is associated with poor prognosis and reduced disease-free survival.(2,3) Trastuzumab (Herceptin; Genentech, San Francisco, CA), a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), has been successfully…”
The Role of Breast Cancer Stem Cells in Metastasis and Therapeutic Implications
Velasco-Velázquez, M. A., Popov, V. M., Lisanti, M. P., & Pestell, R. G. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.03.005 · Cited by 178
“The HER2 gene (ERBB2) is amplified in 20% to 30% of human breast cancers and is associated with the metastatic phenotype.(46) The role of HER2 amplification in CSC expansion is supported by multiple lines of evidence: i) HER2 overexpression correlated with the expression of the stem cell marker ALDH in breast cancer p…”
BackgroundCorrelation between NK function and response to trastuzumab in metastatic breast cancer patients
Beano, A., Signorino, E., Evangelista, A., Brusa, D., Mistrangelo, M., Polimeni, M. A., Spadi, R., Donadio, M., Ciuffreda, L., & Matera, L. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-25 · Cited by 155
“Human Epidermal Growth Factor Receptor 2 (Her2), a member of the ErbB family that plays an important role in promoting oncogenic transformation and tumour growth [2] is overexpressed in 20–30% of patients [3,4].”
Transgenic mouse models of human breast cancer
Hutchinson, J. N., & Muller, W. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203970 · Cited by 178
Rhodes, A., Jasani, B., Anderson, E. L., Dodson, A. R., & Balaton, A. J. (2002) · American Journal of Clinical Pathology · doi:10.1309/97wn-w6ux-xjwt-02h2 · Cited by 178
“Key Words: HER-2/neu; Cell lines; Breast tumors; Immunohistochemistry; Assay sensitivity; Evaluation A b s t r a c t Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4 formalin-fixed, paraffin-processed breast and ovarian carcinoma cell lines with graded levels of HER-2/neu protein…”
MethodThe Politics of Personalised Medicine: Pharmacogenetics in the Clinic
Hedgecoe, A. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511489136 · Cited by 177
Metabolic Regulation of Apoptosis in Cancer
(2016) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.06.006 · Cited by 177
Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer
Mercogliano, M. F., Bruni, S., Elizalde, P. V., & Schillaci, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00584 · Cited by 177
“HER2-Positive Subtype Expression of the HER2 receptor is found in 13–20% of breast cancers (142), contributing to oncogenic transformation, a more aggressive phenotype and the worst 4-year survival (82.”
BackgroundTan, A. R., Im, S.-A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., De Laurentiis, M., Pierga, J.-Y., Jung, K. H., Schem, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30536-2 · Cited by 177
Razis, E., Bobos, M., Kotoula, V., Eleftheraki, A. G., Kalofonos, H. P., Pavlakis, K., Papakostas, P., Aravantinos, G., Rigakos, G., Efstratiou, I., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1572-5 · Cited by 177
“associated with worse prognosis and increased rates of disease recurrence [1].”
BackgroundSperinde, J., Jin, X., Banerjee, J., Penuel, E., Saha, A., Diedrich, G., Huang, W., Leitzel, K., Weidler, J., Ali, S. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0410 · Cited by 177
“Elevated expression of HER2 is found in 25% to 30% of breast cancers and is associated with poor prognosis (2, 3).”
BackgroundTokunaga, E., Kimura, Y., Oki, E., Ueda, N., Futatsugi, M., Mashino, K., Yamamoto, M., Ikebe, M., Kakeji, Y., Baba, H., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21358 · Cited by 177
Goodwin, P. J., Stambolic, V., Lemieux, J., Chen, B. E., Parulekar, W. R., Gelmon, K. A., Hershman, D. L., Hobday, T. J., Ligibel, J. A., Mayer, I. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1224-1 · Cited by 177
“One successful example of this molecularly based, stepwise approach in breast cancer involved the identification of the HER2/neu receptor as a key driver of growth in a subset of breast cancers [ 1 ].”
BackgroundTreating Breast Cancer in the 21st Century: Emerging Biological Therapies
Tinoco, G., Warsch, S., Glück, S., Avancha, K., & Montero, A. J. (2013) · Journal of Cancer · doi:10.7150/jca.4925 · Cited by 176
Zhang, M., Zhang, Y., Zhang, L., & Tian, Q. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.02.013 · Cited by 176
HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications
Krüger, S., Weitsch, G., Büttner, H., Matthiensen, A., Böhmer, T., Marquardt, T., Sayk, F., Feller, A. C., & Böhle, A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10731 · Cited by 176
Alpy, F., Stoeckel, M.-E., Dierich, A., Escola, J.-M., Wendling, C., Chenard, M.-P., Vanier, M. T., Gruenberg, J., Tomasetto, C., & Rio, M.-C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006279200 · Cited by 176
Park, Y. H., Park, M. J., Ji, S. H., Yi, S. Y., Lim, D. H., Nam, D. H., Lee, J.-I., Park, W., Choi, D. H., Huh, S. J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604941 · Cited by 176
“In HER2-overexpressing breast cancer, which is associated with a high recurrence rate and poor outcome (Slamon et al, 1987; Paik et al, 1990; Kallioniemi et al, 1991; Boss et al, 2003), trastuzumab-based therapies are well established and regarded as a standard therapy (Slamon et al, 2001; Pegram…”
BackgroundHER-2 and Topoisomerase II As Predictors of Response to Chemotherapy
Pritchard, K. I., Messersmith, H., Elavathil, L., Trudeau, M., O’Malley, F., & Dhesy-Thind, B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4716 · Cited by 176
Staaf, J., Ringnér, M., Vallon-Christersson, J., Jönsson, G., Bendahl, P.-O., Holm, K., Arason, A., Gunnarsson, H., Hegardt, C., Agnarsson, B. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8775 · Cited by 175
ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases
Spencer, K. S. R., Graus-Porta, D., Leng, J., Hynes, N. E., & Klemke, R. L. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.2.385 · Cited by 175
“In fact, ErbB2 amplification is used as an independent prognostic indicator of patient survival and is correlated with a number of adverse prognostic factors in breast cancer, including increased occurrence of metastasis and micrometastatic bone marrow disease (Slamon et al., 1987; Pantel et al., 1993).”
BackgroundHuang, H. J., Neven, P., Drijkoningen, M., Paridaens, R., Wildiers, H., Van Limbergen, E., Berteloot, P., Amant, F., Vergote, I., & Christiaens, M. R. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.022772 · Cited by 175
Ihara, S., Miyoshi, E., Ko, J. H., Murata, K., Nakahara, S., Honke, K., Dickson, R. B., Lin, C.-Y., & Taniguchi, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200673200 · Cited by 175
Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
Rayego-Mateos, S., Rodrigues-Diez, R., Morgado-Pascual, J. L., Valentijn, F., Valdivielso, J. M., Goldschmeding, R., & Ruiz-Ortega, M. (2018) · Mediators of Inflammation · doi:10.1155/2018/8739473 · Cited by 175
Selective Cleavage of the Heregulin Receptor ErbB-4 by Protein Kinase C Activation
Vecchi, M., Baulida, J., & Carpenter, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18989 · Cited by 175
Seo, A. N., Kwak, Y., Kim, D.-W., Kang, S.-B., Choe, G., Kim, W. H., & Lee, H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098528 · Cited by 175
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
Amin, D. N., Sergina, N., Ahuja, D., McMahon, M., Blair, J. A., Wang, D., Hann, B., Koch, K. M., Shokat, K. M., & Moasser, M. M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000389 · Cited by 175
Kim, K. C., Koh, Y. W., Chang, H.-M., Kim, T. H., Yook, J. H., Kim, B. S., Jang, S. J., & Park, Y. S. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1695-2 · Cited by 175
“HER2 gene amplification, which occurs in 20–25% of breast cancers, has been recognized as a prognostic and predictive marker in breast cancer.(7) Humanized mouse monoclonal antibody-based therapy targeting HER2 is now being used not only in metastatic cases but also is being applied as an adjuvant therapy.”
BackgroundAsian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H. M., McClure, L. A., Lichtensztajn, D., Ford, J. M., & Gomez, S. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1173-8 · Cited by 174
“HER2-positive breast cancer has an aggressive clinical course with poorer breast cancer-specific survival than most other breast cancer subtypes [2, 6].”
Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder
Coombs, L., Pigott, D., Sweeney, E., Proctor, A., Eydmann, M., Parkinson, C., & Knowles, M. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.139 · Cited by 174
“%) reported for breast and ovarian tumours (Zhou et al., 1989; Slamon et al., 1987, 1989).”
BackgroundTrastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
Maadi, H., Soheilifar, M. H., Choi, W.-S., Moshtaghian, A., & Wang, Z. (2021) · Cancers · doi:10.3390/cancers13143540 · Cited by 173
“found that the HER2 gene is amplified in about 30% of BC tumors, and this amplification is significantly correlated with poor prognosis in BC patients [5].”
BackgroundHicks, D. G., & Tubbs, R. R. (2005) · Human Pathology · doi:10.1016/j.humpath.2004.11.010 · Cited by 173
The role of overexpressed HER2 in transformation
Neve, R. M., Lane, H. A., & Hynes, N. E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s9 · Cited by 173
“[12] first observed that HER2-gene amplification independently predicted overall (OS) and diseasefree survival (DFS), and many studies have confirmed that HER2 overexpression is an indicator of poor prognosis in women with breast cancer.”
BackgroundNoonberg, S. B., & Benz, C. C. (2000) · Drugs · doi:10.2165/00003495-200059040-00003 · Cited by 173
“In the clinic, overexpression of c-erbB2/HER2/ neu (hereafter referred to as HER2) and/or the epidermal growth factor receptor erbB1/HER1/EGFR (hereafter referred to as EGFR) in tumour isolates correlates with poorer prognosis and shorter survival times for patients with breast and ovarian cancers.[21-23] Additionally…”
Background131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
D'Huyvetter, M., De Vos, J., Xavier, C., Pruszynski, M., Sterckx, Y. G. J., Massa, S., Raes, G., Caveliers, V., Zalutsky, M. R., Lahoutte, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0310 · Cited by 173
“Its incidence in breast cancer is about 20%–30% and is often associated with a higher recurrence rate and a shorter time to relapse (2, 3).”
BackgroundOncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
Berns, E. M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., Portengen, H., & Klijn, J. G. M. (1995) · Gene · doi:10.1016/0378-1119(94)00534-y · Cited by 173
Esparís-Ogando, A., Díaz-Rodríguez, E., Montero, J. C., Yuste, L., Crespo, P., & Pandiella, A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.270-285.2002 · Cited by 172
G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer
Ignatov, A., Ignatov, T., Weißenborn, C., Eggemann, H., Bischoff, J., Semczuk, A., Roessner, A., Costa, S. D., & Kalinski, T. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1584-1 · Cited by 172
“An amplification and overexpression of HER-2 gene and increased protein expression occurs in about 12–25% of the human breast cancers [24–26].”
Fiegl, H., Millinger, S., Goebel, G., Müller-Holzner, E., Marth, C., Laird, P. W., & Widschwendter, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2508 · Cited by 172
“The her-2 gene is amplified and overexpressed in 20% to 30% of invasive breast carcinomas and is associated with increased metastatic potential and decreased overall survival (2, 3).”
Rhodes, D. R., Ateeq, B., Cao, Q., Tomlins, S. A., Mehra, R., Laxman, B., Kalyana-Sundaram, S., Lonigro, R. J., Helgeson, B. E., Bhojani, M. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900351106 · Cited by 172
“In breast cancer research, this strategy has been realized with the study of ERBB2, which is amplified and overexpressed in 25–30% of breast tumors (1, 2), directly contributing to tumorigenesis (3, 4).”
BackgroundHistological evaluation of AMPK signalling in primary breast cancer
Hadad, S. M., Baker, L., Quinlan, P. R., Robertson, K. E., Bray, S. E., Thomson, G., Kellock, D., Jordan, L. B., Purdie, C. A., Hardie, D. G., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-307 · Cited by 172
“FAS is up-regulated in about 50% of breast cancers, is an indicator of poor prognosis, and is associated with the HER2 oncogene [22-24].”
BackgroundNew Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2291 · Cited by 172
Ben-Kasus, T., Schechter, B., Lavi, S., Yarden, Y., & Sela, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812059106 · Cited by 172
Burcombe, R. J., Makris, A., Richman, P. I., Daley, F. M., Noble, S., Pittam, M., Wright, D., Allen, S. A., Dove, J., & Wilson, G. D. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602256 · Cited by 172
“Human epidermal growth factor (HER-2) overexpression has been associated with poor overall prognosis, shorter relapse-free and overall survival (Slamon et al, 1987), sensitivity to optimal dose anthracycline chemotherapy (Thor et al, 1998) and resistance to adjuvant anthracycline chemotherapy and…”
BackgroundMultivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
Yuan, H., Jiang, W., von Roemeling, C. A., Qie, Y., Liu, X., Chen, Y., Wang, Y., Wharen, R. E., Yun, K., Bu, G., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.69 · Cited by 172
Lo, T. L., Yusoff, P., Fong, C. W., Guo, K., McCaw, B. J., Phillips, W. A., Yang, H., Wong, E. S. M., Leong, H. F., Zeng, Q., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1207 · Cited by 171
“The breast cancers showing at least an arbitrary 2-fold up-regulation in signal were considered to exhibit an up-regulation in expression of ErbB2.”
BackgroundInfluentialGene amplification and tumor progression
Brison, O. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90020-d · Cited by 171
Molecular Classification of Breast Carcinomas Using Tissue Microarrays
Callagy, G., Cattaneo, E., Daigo, Y., Happerfield, L., Bobrow, L. G., Pharoah, P. D. P., & Caldas, C. (2003) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200303000-00004 · Cited by 171
The c ‐ erbB ‐ 2 proto‐oncogene in human pancreatic cancer
Hall, P. A., Hughes, C. M., Staddon, S. L., Richman, P. I., Gullick, W. J., & Lemoine, N. R. (1990) · The Journal of Pathology · doi:10.1002/path.1711610305 · Cited by 171
Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development
Tan, D. S. W., Thomas, G. V., Garrett, M. D., Banerji, U., de Bono, J. S., Kaye, S. B., & Workman, P. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bd0445 · Cited by 171
Won, H. S., Ahn, J., Kim, Y., Kim, J. S., Song, J.-Y., Kim, H.-K., Lee, J., Park, H. K., & Kim, Y.-S. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01519-x · Cited by 171
Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging
Lee, S. B., Hassan, M., Fisher, R., Chertov, O., Chernomordik, V., Kramer-Marek, G., Gandjbakhche, A., & Capala, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4076 · Cited by 171
Immunity to Oncogenic Proteins
Cheever, M. A., Disis, M. L., Bernhard, H., Gralow, J. R., Hand, S. L., Huseby, E. S., Qin, H. L., Takahashi, M., & Chen, W. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00076.x · Cited by 171
Functional Copy-Number Alterations in Cancer
Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003179 · Cited by 170
Cortés, J., Hurvitz, S. A., Im, S.-A., Iwata, H., Curigliano, G., Kim, S.-B., Chiu, J. W. Y., Pedrini, J. L., Li, W., Yonemori, K., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03021-7 · Cited by 169
Trastuzumab: hopes and realities
Leyland-Jones, B. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00676-9 · Cited by 169
Xu, Z., Guo, D., Jiang, Z., Tong, R., Jiang, P., Bai, L., Chen, L., Zhu, Y., Guo, C., Shi, J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111682 · Cited by 168
Miller, K., Cortes, J., Hurvitz, S. A., Krop, I. E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J. G., Wickham, T. J., Molnar, I., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2385-z · Cited by 168
“Approximately 20 % of breast cancers are human epidermal growth factor receptor 2 (HER2)-positive, which represents a particularly aggressive subtype [1, 2].”
BackgroundMolecular predictors of response to trastuzumab and lapatinib in breast cancer
Esteva, F. J., Yu, D., Hung, M.-C., & Hortobagyi, G. N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 168
Cossetti, R. J. D., Tyldesley, S. K., Speers, C. H., Zheng, Y., & Gelmon, K. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2461 · Cited by 168
“Recently, a distinction between the HER2overexpressing cancers according to ER status has been described.(29) We have shown that the timing and patterns of relapse differ according to BC molecular subtypes and that these patterns persist with current therapies, albeit with better overall outcomes.”
Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer
Mellor, H. R., Bell, A. R., Valentin, J.-P., & Roberts, R. R. A. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq378 · Cited by 168
“Trastuzumab (Herceptin), approved in 1998, is a humanized monoclonal antibody that inhibits the RTK human epidermal growth factor receptor-2 (ErbB2), which is overexpressed in approximately 20–25% of breast cancers (Slamon et al., 1987, 1989).”
BackgroundFarahmand, S., Fernandez, A. I., Ahmed, F. S., Rimm, D. L., Chuang, J. H., Reisenbichler, E., & Zarringhalam, K. (2022) · Modern Pathology · doi:10.1038/s41379-021-00911-w · Cited by 167
Lark, A. L., Livasy, C. A., Dressler, L., Moore, D. T., Millikan, R. C., Geradts, J., Iacocca, M., Cowan, D., Little, D., Craven, R. J., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800424 · Cited by 167
Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx494 · Cited by 167
“HER2-overexpressing BC is a biologically aggressive subtype occurring in about 15%–25% of newly diagnosed cases [1].”
BackgroundCarney, W. P., Neumann, R., Lipton, A., Leitzel, K., Ali, S., & Price, C. P. (2003) · Clinical Chemistry · doi:10.1373/49.10.1579 · Cited by 167
Xia, W., Chen, J.-S., Zhou, X., Sun, P.-R., Lee, D.-F., Liao, Y., Zhou, B. P., & Hung, M.-C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0527 · Cited by 166
Pertuzumab: new hope for patients with HER2-positive breast cancer
Capelan, M., Pugliano, L., De Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C., Loi, S., & Piccart-Gebhart, M. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds328 · Cited by 166
“Approximately 15% to 20% of patients with breast cancer (BC) have human epidermal growth factor receptor 2 (HER2) overexpression or amplification, associated with poorer prognosis [1–3].”
BackgroundSuter, T. M., Cook-Bruns, N., & Barton, C. (2004) · The Breast · doi:10.1016/j.breast.2003.09.002 · Cited by 166
Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06280-x · Cited by 165
“The gene encoding epidermal growth factor receptor-2 (HER2/ErbB2) is amplified in approximately 15–20% of breast cancers, conferring poor prognosis and low overall survival [1].”
BackgroundSRC gene expression in human cancer: the role of transcriptional activation
Dehm, S. M., & Bonham, K. (2004) · Biochemistry and Cell Biology · doi:10.1139/o03-077 · Cited by 165
Nicholson, S., Richard, J., Sainsbury, C., Halcrow, P., Kelly, P., Angus, B., Wright, C., Henry, J., Farndon, Jr., & Harris, A. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.30 · Cited by 165
Biscardi, J. S., Belsches, A. P., & Parsons, S. J. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199804)21:4<261::aid-mc5>3.0.co;2-n · Cited by 165
Strategies for immunotherapy of cancer
Melief, C. J. M., Toes, R. M., Medema, J. P., Van Der Burg, S. H., Ossendorp, F., & Offringa, R. (2000) · Advances in Immunology · doi:10.1016/s0065-2776(00)75006-1 · Cited by 165
Targeting HER2 in other tumor types
Scholl, S., Beuzeboc, P., & Pouillart, P. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s81 · Cited by 164
Finn, R. S., Press, M. F., Dering, J., Arbushites, M., Koehler, M., Oliva, C., Williams, L. S., & Di Leo, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1925 · Cited by 164
Dankort, D., Maslikowski, B., Warner, N., Kanno, N., Kim, H., Wang, Z., Moran, M. F., Oshima, R. G., Cardiff, R. D., & Muller, W. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1540-1551.2001 · Cited by 163
“Neu or ErbB-2 amplification and elevated expression has been implicated in the etiology of human ovarian and breast cancers and correlates with a poor clinical prognosis in breast cancer patients (3, 44 , 45).”
BackgroundEGFR, HER2 and VEGF Pathways: Validated Targets for Cancer Treatment
Press, M. F., & Lenz, H.-J. (2007) · Drugs · doi:10.2165/00003495-200767140-00006 · Cited by 163
Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
Palomeras, S., Ruiz-Martínez, S., & Puig, T. (2018) · Molecules · doi:10.3390/molecules23092193 · Cited by 163
Regulation of Epithelial Cell Migration and Tumor Formation by β-Catenin Signaling
Müller, T., Bain, G., Wang, X., & Papkoff, J. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5630 · Cited by 163
Mackay, A., Jones, C., Dexter, T., Silva, R. L. A., Bulmer, K., Jones, A., Simpson, P., Harris, R. A., Jat, P. S., Neville, A. M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206349 · Cited by 163
“Overexpression of the proto-oncogene ERBB2 (HER2/neu) is observed in 25– 30% of all such cancers, and is an established adverse prognostic factor (Slamon et al., 1987, 1989; Ross and Fletcher, 1999; Menard et al., 2001) yielding a median survival of 3 years, compared with 6–7 years when…”
BackgroundHER2 and Breast Cancer — A Phenomenal Success Story
Hayes, D. F. (2019) · New England Journal of Medicine · doi:10.1056/nejmcibr1909386 · Cited by 163
HER2 testing: Current status and future directions
Perez, E. A., Cortés, J., Gonzalez-Angulo, A. M., & Bartlett, J. M. S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.001 · Cited by 161
“time to relapse, and an increased incidence of metastases [3–5].”
BackgroundClinical Uses of Tumor Markers: A Critical Review
Duffy, M. J. (2001) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/20014091084218 · Cited by 161
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Insights into the biological functions of Dock family guanine nucleotide exchange factors
Laurin, M., & Côté, J.-F. (2014) · Genes & Development · doi:10.1101/gad.236349.113 · Cited by 160
“The RTK HER2 is amplified or overexpressed in 20%–30% of breast cancers (Slamon et al. 1987).”
BackgroundBRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer
James, C. R., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-142 · Cited by 160
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
Seung, E., Xing, Z., Wu, L., Rao, E., Cortez-Retamozo, V., Ospina, B., Chen, L., Beil, C., Song, Z., Zhang, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04439-0 · Cited by 160
c-kit protein, a transmembrane kinase: identification in tissues and characterization.
Majumder, S., Brown, K., Qiu, F. H., & Besmer, P. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.11.4896 · Cited by 160
“In addition, overexpression of tyrosine kinase receptors such as c-erbB2 as seen in mammary carcinoma or NIH 3T3 cells may provide a sufficient amplification of a basal kinase activity to function in signal transduction (18, 21, 32).”
BackgroundReceptor Tyrosine Kinases and Targeted Cancer Therapeutics
Takeuchi, K., & Ito, F. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1774 · Cited by 159
Wu, J., Lee, C., Yokom, D., Jiang, H., Cheang, M. C. U., Yorida, E., Turbin, D., Berquin, I. M., Mertens, P. R., Iftner, T., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3561 · Cited by 159
“EGFR and HER-2 are overexpressed in f15% (17) and f20% of breast cancers (18), respectively.”
BackgroundHarrington, S., Padua, D., Battaglini, C., Michener, L. A., Giuliani, C., Myers, J., & Groff, D. (2011) · Journal of Cancer Survivorship · doi:10.1007/s11764-010-0168-0 · Cited by 159
Disis, M. L., Knutson, K. L., Schiffman, K., Rinn, K., & McNeel, D. G. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006438507898 · Cited by 159
“HER-2/neu overexpression carries a poor prognosis, in particular, in advanced stage breast and ovarian cancers [18] and thus, defines a patient population needing novel treatment options.”
Background
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.